---
title: "Century Therapeutics 2025 net loss narrows beating estimates"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278880556.md"
datetime: "2026-03-12T12:10:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278880556.md)
  - [en](https://longbridge.com/en/news/278880556.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278880556.md)
---

# Century Therapeutics 2025 net loss narrows beating estimates

)

Overview

-   US biotechnology firm’s 2025 net loss narrowed, beating analyst expectations
-   Collaboration revenue for 2025 surged, driven by Bristol-Myers Squibb agreement
-   Company completed $135 mln private placement, extending cash runway into Q1 2029

Outlook

-   Century expects to submit CNTY-813 IND in 4Q 2026, with initial clinical data in 2H 2027
-   Company expects CNTY-308 to enter the clinic in 2026, pending regulatory clearance
-   Century anticipates updated preliminary clinical data from the CARAMEL study in 2026

Result Drivers

-   COLLABORATION REVENUE - Surge in collaboration revenue attributed to Bristol-Myers Squibb agreement
-   LOWER R&D AND G&A COSTS - Decline in research and development and administrative expenses due to reduced personnel, manufacturing, and legal costs Company press release:

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

### FY $109.16

Collabor mln

ation

Revenue

FY Net Beat -$9.58 -$14.72

Income mln mln (3

Analysts

)

FY Beat -$17.27 -$20.86

Operatin mln mln (3

g Income Analysts

)

FY Basic -$0.14

### EPS

### FY $126.43

Operatin mln

g

Expenses

Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 5 “strong buy” or “buy”, 1 “hold” and no “sell” or “strong sell”
-   The average consensus recommendation for the biotechnology & medical research peer group is “buy”
-   Wall Street’s median 12-month price target for Century Therapeutics Inc is $4.00, about 46.5% above its March 11 closing price of $2.73 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### Related Stocks

- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [RXL.US](https://longbridge.com/en/quote/RXL.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IPSC.US](https://longbridge.com/en/quote/IPSC.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [PILL.US](https://longbridge.com/en/quote/PILL.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [KALA BIO 10-K: Operating loss $39.16M; Net loss $26.98M](https://longbridge.com/en/news/282893053.md)
- [ZAWYA: CE-Ventures announces acquisition of portfolio company CrossBridge Bio by Eli Lilly](https://longbridge.com/en/news/282695762.md)
- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)
- [Oragenics Doses First Patient In Phase 2a Trial For Brain Injury Drug ONP-002](https://longbridge.com/en/news/282660503.md)
- [Cytokinetics Highlights MYQORZO Launch Progress, Teases 2026 Phase 3 Readout at Needham Conference](https://longbridge.com/en/news/282596648.md)